
    
      The primary objective is to determine the maximum tolerated dose (MTD) and/or recommended
      Phase 2 dose (RP2D) of elacestrant in patients with advanced ER+HER2-negative breast cancer.

      The secondary objectives of this study are:

        -  To assess the safety and tolerability of elacestrant

        -  To evaluate the pharmacokinetics (PK) of elacestrant

        -  To evaluate the preliminary anti-tumor effect of elacestrant
    
  